Scarica l'app Stockscreener
14.77
0.47%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
5 Best Large Cap Stocks Under $30 With Highest Upside Potential - Insider Monkey
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data - Insider Monkey
Summit falls despite Phase 3 ivonescimab data in NSCLC - MSN
Insider Buying: Manmeet Soni Acquires 50,000 Shares of Summit Th - GuruFocus
Summit Therapeutics COO & CFO Soni buys $722,250 in stock By Investing.com - Investing.com South Africa
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stock By Investing.com - Investing.com South Africa
Summit Therapeutics co-CEO Zanganeh Mahkam buys $1.46m stock - Investing.com UK
Summit Therapeutics (SMMT) Co‑CEO associated trust purchases 100,000 shares at $14.60 - Stock Titan
Summit Therapeutics (SMMT) co-CEO buys 100K shares via revocable trust - Stock Titan
Summit Therapeutics Insider Bought Shares Worth $722,250, According to a Recent SEC Filing - marketscreener.com
Summit Therapeutics COO, CFO Purchased Shares Worth Over $722K - TradingView
Summit Therapeutics COO & CFO Soni buys $722,250 in stock - Investing.com
Executive Manmeet Singh Soni buys 50K Summit Therapeutics (SMMT) shares - Stock Titan
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference - Yahoo Finance
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy - Yahoo Finance
Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC - Insider Monkey
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile - Yahoo Finance
Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology CongressSlideshow (NASDAQ:SMMT) 2026-06-03 - Seeking Alpha
Summit Therapeutics Enables Affiliate and Insider Share Purchases - TipRanks
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics directors, executives likely to buy shares under ATM program - TradingView
Summit Therapeutics (SMMT) leaders may buy shares via existing ATM - Stock Titan
Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus - Gotrade
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT) - The Globe and Mail
Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments - Insider Monkey
Summit Therapeutics (SMMT) Sheds 10.4%, This Analyst is Pessimistic - Insider Monkey
Summit Therapeutics (SMMT) Shares Drop Despite Positive Cancer T - GuruFocus
Exclusive BAC Article: Akeso And Summit: Positive China HARMONi-6 Trial Ivonescimab Squamous NSCLC, HARMONi-3 Data From Summit 2nd Half 2026 & 1st Half 2027, And Catalysts (OTCMKTS:AKESF) - Seeking Alpha
Summit Therapeutics (SMMT) Slides As Bearish Calls Mount - StocksToTrade
Summit Therapeutics Inc. (SMMT) once dropped over 12.8%, approaching the May 1st low of $15.14. - Bitget
Summit Therapeutics Reports Promising Phase II Ivonescimab Results in Metastatic Colorectal Cancer at ASCO 2026 - Minichart
Summit Therapeutics slides as traders digest ASCO ivonescimab update - Quiver Quantitative
Summit Therapeutics (SMMT) Revenue BreakdownMain Composition - Moomoo
What's Going On With Summit Therapeutics Stock On Monday? - Benzinga
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $7.7 to $40 - Moomoo
Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet - Yahoo Finance
Bernstein reiterates Summit Therapeutics stock Underperform on trial concerns By Investing.com - Investing.com Canada
Summit Therapeutics stock maintained at Overweight by Cantor on positive trial data - Investing.com Canada
Stifel reiterates Summit Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Summit drops as concerns over older patients cloud cancer trial data - marketscreener.com
Summit Therapeutics Reports Strong Interim Ivonescimab Phase II Data - TipRanks
Summit Therapeutics (SMMT) posts positive ASCO 2026 ivonescimab survival and response data - Stock Titan
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - marketscreener.com
Summit Therapeutics Inc. (SMMT) Stock Analysis: A Potential 62.66% Upside In Biotech Innovation - DirectorsTalk Interviews
SMMT Stock Surges Overnight: Cancer Drug Survival Win Raises The Bar As PFE, BMY, MRK Chase Keytruda's Successor - Yahoo Finance
Summit Therapeutics (SMMT) Unveils Promising Results from Colore - GuruFocus
Summit Therapeutics (SMMT) to Present Phase III Trial Results at ASCO 2026 - GuruFocus
13 Best Short Squeeze Stocks to Invest In - Insider Monkey
Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote & History - Yahoo Finance
New drug combo keeps more lung cancer patients alive at 2 years - Stock Titan
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China - CNBC
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 - Business Wire
1.13%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):